Tirzepatide (Zepbound) came out on top against semaglutide (Wegovy) for treating obesity in the head-to-head SURMOUNT-5 trial ...

"Antihypertensive medication administration time did not affect the risks and benefits of blood pressure-lowering medication ...

Long-term human albumin therapy failed to significantly improve long-term survival outcomes in cirrhotic patients with acute ...

Like many of the almost 100,000 medical students in the U.S., I enrolled in medical school having grown up infatuated with ...

Patients with high-risk advanced ovarian cancer obtained a marginal survival benefit with the addition of bevacizumab ...

Means argues that the cause of most health conditions -- including cancer, Alzheimer's disease, obesity, erectile dysfunction ...

President Trump on Monday signed a sweeping executive order setting a 30-day deadline for drugmakers to lower the cost of ...

The FDA and NIH announced a joint nutrition research venture to better understand the causes of diet-related chronic disease, ...

Early findings from the SPARTAN phase II trial, presented at the National Kidney Foundation (NKF) Spring Clinical Meeting, ...

Tacrolimus outshined another immunosuppressive drug at extending relapse-free survival in kids with frequently relapsing or ...

"Although treatment with stimulants has been found to be effective at reducing ADHD symptoms in children and adolescents, ...

Mathura (a.k.a. "Dr. M") is an ob/gyn resident at a university program in the Southeast U.S. She is passionate about the surgical aspects of ob/gyn and public health research. When she isn't in the ...